Jaguar Health公司获得240K美元FDA赠款, 用于研究Canalevia-CA1, 治疗狗的化疗腹泻, 需要完全批准。 Jaguar Health gets $240K FDA grant to study Canalevia-CA1 for dogs' chemotherapy diarrhea, needed for full approval.

Jaguar Health于2026年1月1日从林业发展局兽医医学中心获得一笔240 000美元的赠款,用于支持一项有关Canaleva-CA1的研究。 CA1是一种有条件批准的药物,用于对狗进行化疗引起的腹泻。 Jaguar Health received a $240,000 grant from the FDA’s Center for Veterinary Medicine on January 1, 2026, to support a study on Canalevia-CA1, a conditionally approved drug for chemotherapy-induced diarrhea in dogs. 条件批准,续签第五年和最后一年至2026年12月21日,需要成功完成有效性研究才能获得FDA的全面批准. The conditional approval, renewed for a fifth and final year through December 21, 2026, requires successful completion of an effectiveness study for full FDA approval. 在接受癌症治疗的狗中,CID是一种常见和严重的副作用,破坏了许多人的化疗计划。 CID is a common and serious side effect in dogs undergoing cancer treatment, disrupting chemotherapy plans for many. 这种药物,而不是抗生素,仅允许在兽医监督下的狗使用,并警告其副作用,如脱水和呕吐。 The drug, not an antibiotic, is approved only for dogs under veterinary supervision, with warnings about side effects like dehydration and vomiting. 狗被认为是与人类化疗有关的腹泻病的相关模型。 Dogs are considered a relevant model for human chemotherapy-related diarrhea.